Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001871630 | SCV002112609 | pathogenic | not provided | 2024-01-16 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Ser443Alafs*12) in the ARSG gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 83 amino acid(s) of the ARSG protein. This variant is present in population databases (rs751461705, gnomAD 0.02%). This premature translational stop signal has been observed in individual(s) with clinical features of Usher syndrome (PMID: 33300174; Invitae). ClinVar contains an entry for this variant (Variation ID: 992583). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this premature translational stop signal affects ARSG function (PMID: 33300174). For these reasons, this variant has been classified as Pathogenic. |
Division of Genetic Medicine, |
RCV001281078 | SCV001451721 | pathogenic | Usher syndrome, type 4 | 2020-12-23 | no assertion criteria provided | clinical testing | |
OMIM | RCV001281078 | SCV001572338 | pathogenic | Usher syndrome, type 4 | 2023-08-17 | no assertion criteria provided | literature only |